SalaryGuide
AboutPricingFor Employers

Marketing jobs

5 marketing jobs

Compass Pathways logo
2 months ago

Director, Payer Marketing

Compass Pathways

New York City, NY (Hybrid)Full time$230K/yr – $260K/yr
Compass Pathways logo
2 months ago

Director, Patient Marketing

Compass Pathways

New York City, NY (Remote)Full time$220K/yr – $270K/yr
Compass Pathways logo
2 months ago

Coordinator, Marketing

Compass Pathways

New York, USA (Hybrid)Full time$80K/yr – $100K/yr
Compass Pathways logo
2 months ago

Director, HCP Marketing

Compass Pathways

New York, USA (Hybrid)Full time$220K/yr – $270K/yr
Compass Pathways logo
3 months ago

Senior Manager, Social Media and Integrated Marketing (Contract)

Compass Pathways

New York, USA (Hybrid)Contract$130K/yr – $190K/yr

All marketing roles in the US

Get alerts for this search

All marketing roles in the US

Get alerts for this search

5 jobs
Compass Pathways logo

Director, Payer Marketing

Compass Pathways

New York City, NY (Hybrid)

$230K/yr - $260K/yrIn-houseFull-timeDirector/executive8+ years exp.
2 months ago
Compass Pathways logo

Director, Patient Marketing

Compass Pathways

New York City, NY (Remote)

$220K/yr - $270K/yrIn-houseFull-timeDirector/executive10+ years exp.
2 months ago
Compass Pathways logo

Coordinator, Marketing

Compass Pathways

New York, USA (Hybrid)

$80K/yr - $100K/yrIn-houseFull-timeMid level2+ years exp.
2 months ago
Compass Pathways logo

Director, HCP Marketing

Compass Pathways

New York, USA (Hybrid)

$220K/yr - $270K/yrIn-houseFull-timeDirector/executive10+ years exp.
2 months ago
Compass Pathways logo

Senior Manager, Social Media and Integrated Marketing (Contract)

Compass Pathways

New York, USA (Hybrid)

$130K/yr - $190K/yrIn-houseContractSenior level8+ years exp.
3 months ago
Compass Pathways logo
Compass Pathways

Director, Payer Marketing

New York City, NY (Hybrid)

$230K/yr – $260K/yrDirector/Executive8+ years expFull time

Posted 2 months ago

Top 1% of applicants do these two things.

The other 99% submit and hope. You're about to do something different.

Job Summary

Own payer access enablement by shaping payer-facing messaging, collateral, and training, while coordinating cross-functional teams to land COMP360 in payer channels.

  • Payer marketing ownership: develop payer segment strategies and collateral for US payers across commercial, Medicare, Medicaid, and VA/DoD/Tricare segments.
  • Cross-functional collaboration: lead stakeholder alignment to ensure compliant, payer-ready materials and seamless launch readiness.
  • Enablement & feedback: train Payer Account Directors and refine value props based on payer feedback and market needs.

Job Description

Responsibilities

  • Develop payer segment strategies and promotional collateral/tools for US payers, including health plans, PBMs (and PBM-affiliated GPOs) across the Commercial, Medicare, Medicaid, VA/DOD/Tricare market segments
  • Create a Payer Value Proposition deck for COMP360 that will be used as the primary tool for Payer Account Directors to educate payers on COMP360
  • Lead the coordination, engagement, and collaboration efforts with all stakeholder teams (internal and external) to ensure that all payer marketing materials successfully address the needs of our payer customers, while both supporting organizational goals and ensuring compliance Especially important will be working directly with the Payer Accounts Team on the design and purpose of these materials
  • Assist in creation of models, dashboards and analysis supporting early product access
  • Work with 3 rd party agency to design and produce effective payer marketing collateral/tools
  • Where applicable, develop Payer Account Director training on the tools and collateral created
  • Monitor feedback from payer customers and stakeholder teams to improve messaging, value prop, and tools consistently over time
  • Serve as a critical member of the cross-functional teams preparing for a successful launch of COMP360 to achieve optimal payer access and coverage

Requirements

  • Bachelor's degree
  • Minimum of eight (8) years combined experience in Pharmaceutical Marketing, Account Management, Managed Markets/Payer Marketing
  • Demonstrated experience with Marketing, Managed Markets, Account Management
  • Demonstrated understanding of the mechanics and economics of the healthcare ecosystem, including influences across various payer segments
  • Demonstrated understanding of healthcare trends and policy issues and their potential impact on business opportunities
  • Deep US Market Access experience across all government and commercial segments
  • Analytic and modeling experience
  • Proven leadership skills with ability to lead across diverse departments, collaborating across stakeholders, and effectively engaging with senior management
  • Demonstrated strategic and critical thinking, problem solving, analytical mindset, planning and communication skills (written/verbal)
  • Participation in and development of early access strategies and related tools:
  • Value messaging
  • Contracting options across segments, inclusive of value-based approaches and alternative payment models
  • Site of care strategy
  • Payer policy inclusion
  • Provider access and reimbursement
  • Medical vs. pharmacy benefit coverage, combined with buy & bill strategy
  • Patient access and OOP
  • Pathway inclusion
  • Legislative policy impact

    Benefits

    • Reasonable accommodation during interview process to be at your best
    • We are committed to building a workplace where everyone’s wellbeing matters
    • We do not discriminate based upon race, religion or belief, colour, nationality, ethnic or national origin, gender, pregnancy or maternity, marital or civil partner status, sexual orientation, gender identity, gender expression, military service, genetic information, familial or marital status, or any other status, category, or characteristic protected by applicable law.
    Compass Pathways logo

    Compass Pathways

    4.7 Glassdoor

    We are Compass Pathways, a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. Our first clinical development programme is researching investigational COMP360 psilocybin treatment for patients with treatment-resistant depression. We want to transform the patient experience in mental health care.

    Founded in 2016
    London, England, GBR
    227 employees (6 in marketing)
    www.compasspathways.com
    92% recommend to a friend
    100% CEO approval

    Traffic Signals

    Monthly Visitors
    28.4K
    Traffic Source Mix
    Search
    48.7%
    Direct
    38.3%
    Referral
    9.2%
    Social
    2.6%
    Paid
    1.1%

    Headcount Trend

    Current headcount: ~230

    Marketing Team

    Marketing Team Size
    4 (2% of company)
    Median Career Experience
    3 years
    Median Tenure
    0.8 years

    People

    HR / Recruitment

    Jessica Muñoz
    Jessica Muñoz
    Talent Acquisition Specialist
    At the company for 10 months

    Funding

    Total Funding
    $771.2M
    Last Raise
    $200M
    Post IPO Equity, 18 days ago

    Funding History

    • Feb 2026
      Post IPO Equity • $200M
    • Feb 2026
      Post IPO Equity • $150M
    • Jan 2025
      Post IPO Equity • $150M

    Recent News

    Watch Compass Pathways Eyes FDA Approval for Psilocybin Depression Drug
    Dec 4, 2025 • Bloomberg.com
    Compass Pathways to Participate in Two Investor Conferences in December
    Nov 20, 2025 • Business Wire
    Compass Pathways at Stifel 2025: Accelerating Launch with Strategic Trials
    Nov 11, 2025 • Investing.com
    Compass Pathways to Participate in Stifel 2025 Healthcare Conference
    Nov 5, 2025 • Business Wire
    COMP360 Timeline Accelerates: Compass Pathways Targets Early Depression Trial Data In 2026
    Nov 5, 2025 • RTTNews
    COMPASS Pathways plc (NASDAQ:CMPS) Q3 2025 Earnings Call Transcript
    Nov 5, 2025 • Insider Monkey
    Compass Pathways to expedite launch of its experimental depression therapy
    Nov 4, 2025 • TradingView
    COMPASS Pathways Plc - American (CMPS) Q3 FY2025 earnings call transcript
    Nov 4, 2025 • Yahoo Finance
    Compass Pathways Accelerates Psilocybin Launch Timeline by 9-12 Months
    Nov 4, 2025 • Psychedelic Alpha
    Compass Pathways expects earlier FDA approval decision on its psilocybin drug
    Nov 4, 2025 • statnews.com
    COMPASS Pathways : investor presentation November 2025
    Nov 4, 2025 • marketscreener.com
    Compass Pathways Announces Third Quarter 2025 Financial Results and Business Highlights Including Acceleration of Commercial Launch Plans by 9-12 Months
    Nov 4, 2025 • Business Wire
    Compass plots quicker path to approval, launch readiness for depression drug
    Nov 4, 2025 • Endpoints News
    Biotech firm Compass Pathways' operating income beats Q3 analyst expectations
    Nov 4, 2025 • TradingView
    Compass Pathways Accelerates Launch Plans Amid Positive FDA Talks
    Nov 4, 2025 • TipRanks
    NeuroKaire Enters into R&D Collaboration with Compass Pathways to Pioneer Precision Treatments for Depression
    Oct 30, 2025 • PR Newswire
    Compass Pathways (NASDAQ: CMPS) joins NeuroKaire to study psychedelics in TRD, MDD
    Oct 30, 2025 • Stock Titan
    Compass Pathways (Nasdaq: CMPS) appoints Jeffrey Jonas to board; Lönngren retiring
    Oct 29, 2025 • Stock Titan
    Compass Pathways Appoints Dr. Jeffrey Jonas to Board of Directors
    Oct 29, 2025 • Yahoo Finance
    Compass Pathways Appoints Dr. Jeffrey Jonas to Board
    Oct 29, 2025 • TipRanks
    Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
    Oct 28, 2025 • BioSpace
    Compass Pathways to Announce Third Quarter Financial Results on November 4, 2025
    Oct 28, 2025 • Business Wire
    Compass Pathways: Maintain Hold Rating With COMP360 Going Beyond TRD Development (CMPS)
    Oct 15, 2025 • Seeking Alpha
    COMPASS Pathways plc (NASDAQ:CMPS) has caught the attention of institutional investors who hold a sizeable 32% stake
    Oct 11, 2025 • Yahoo Finance
    Goldman Sachs Group Inc. Sells 81,540 Shares of COMPASS Pathways PLC Sponsored ADR $CMPS
    Oct 1, 2025 • MarketBeat
    H.C. Wainwright Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $40
    Sep 23, 2025 • 富途牛牛
    Brokerages Set COMPASS Pathways PLC Sponsored ADR (NASDAQ:CMPS) PT at $16.29
    Sep 23, 2025 • MarketBeat
    Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
    Sep 2, 2025 • Yahoo Finance
    Compass Pathways Announces Publication of Results from Phase 2 Study of COMP360 Psilocybin for Post-Traumatic Stress Disorder
    Sep 2, 2025 • Business Wire
    Compass Pathways to Participate in Four Investor Conferences in September
    Aug 27, 2025 • Investing News Network
    Compass Pathways’ Phase III Study on COMP360: A Potential Game-Changer for Treatment-resistant Depression
    Aug 20, 2025 • TipRanks
    PE Plays It Safe in Psychedelic Investments While Venture Goes Bold
    Aug 18, 2025 • Behavioral Health Business
    Psychedelic Drugs Market Research Report 2025-2033 | Rising Demand for Non-Hallucinogenic Psychedelics Expands Patient Base, Breakthrough Regulatory Designations Accelerate Approvals
    Aug 14, 2025 • Research and Markets
    Compass Pathways at Canaccord Conference: Psilocybin Progress
    Aug 12, 2025 • Investing.com
    Six psychedelic drug companies aiming to revolutionize mental health treatment
    Aug 12, 2025 • Labiotech.eu
    Psychedelic Drugs Market Size to Surpass USD 10.11 Billion by 2032, Fueled by Breakthrough Therapies and Expanding Mental Health Applications – SNS Insider
    Aug 12, 2025 • SNS Insider pvt ltd
    Mental Health Biotech Leader Compass Pathways Sets Major Investor Presentation at Canaccord Conference
    Aug 5, 2025 • Stock Titan
    Compass Pathways’ COMP360 Study: A New Hope for Treatment-resistant Depression?
    Aug 4, 2025 • TipRanks
    CCORF Maintains COMPASS Pathways(CMPS.US) With Buy Rating, Maintains Target Price $15
    Aug 1, 2025 • 富途牛牛
    Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
    Jul 31, 2025 • Investing News Network
    Compass Pathways Reports Strong Progress in Q2 2025
    Jul 31, 2025 • TipRanks
    Compass Pathways Announces Second Quarter 2025 Financial Results and Business Highlights
    Jul 31, 2025 • Business Wire
    COMPASS Pathways ADS GAAP EPS of -$0.41 beats by $0.02
    Jul 31, 2025 • Seeking Alpha
    Compass Pathways outlines FDA engagement and accelerated pathways for COMP360 in TRD while advancing PTSD program
    Jul 31, 2025 • Seeking Alpha
    Compass Pathways reports Q2 EPS (41c) vs. (56c) last year
    Jul 31, 2025 • thefly.com
    Compass Pathways Appoints Justin Gover to Board of Directors
    Jul 29, 2025 • Yahoo Finance
    Compass Pathways appoints former GW Pharmaceuticals CEO to board By Investing.com
    Jul 29, 2025 • Investing.com UK
    Compass Pathways Appoints Justin Gover to Board
    Jul 29, 2025 • TipRanks
    Compass Pathways Appoints Justin Gover to Board of Directors
    Jul 29, 2025 • Morningstar.com
    Compass Pathways Appoints Justin Gover to Board of Directors
    Jul 29, 2025 • citybiz
    Institute for Integrative Therapies Launches Psilocybin Depression Study in Collaboration with COMPASS Pathways
    Jul 25, 2025 • EIN Presswire
    Compass Pathways’ Psilocybin Study: A New Hope for Treatment-resistant Depression?
    Jul 24, 2025 • TipRanks
    Lobbying Update: $60,000 of COMPASS PATHWAYS INC. lobbying was just disclosed
    Jul 22, 2025 • Nasdaq
    Cathie Wood’s ARK Adds 125K COMPASS Pathways plc (CMPS) Shares
    Jul 15, 2025 • Yahoo Finance
    Support for psychedelic treatments means full steam ahead at Compass, despite stock drop
    Jul 15, 2025 • Healthcare Brew
    Compass Pathways Phase 3 trial delivers regulatory win, says H.C. Wainwright
    Jul 15, 2025 • thefly.com
    Can Psychedelics Break Through in Depression? Recent Readouts Leave Investors Wanting More
    Jul 14, 2025 • BioSpace
    Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
    Jul 10, 2025 • Business Wire
    Compass Pathways to Participate in HC Wainwright @Home Series Interview on July 14th, 8:00am ET
    Jul 10, 2025 • Stock Titan
    COMPASS Pathways (CMPS) Upgraded to Buy: Here's Why
    Jul 8, 2025 • Yahoo Finance
    Psychedelic: Compass Pathways achieves primary endpoint in COMP360 trial
    Jun 27, 2025 • Yahoo Finance
    Compass Pathways: Psychedelics Drug Data Sends Share Price South - Rating Downgrade (CMPS)
    Jun 25, 2025 • Seeking Alpha
    Cautious Optimism, Lingering Questions: Researchers React to Compass’ Phase 3 Psilocybin Results
    Jun 25, 2025 • Psychedelic Alpha
    Compass’ stock slips despite psilocybin trial hitting target
    Jun 24, 2025 • Clinical Trials Arena
    Compass Pathways Stock: Downgrading To Hold On Released TRD Results With COMP360 (CMPS)
    Jun 24, 2025 • Seeking Alpha
    Compass Pathways price target lowered to $7 by BTIG on drug concerns
    Jun 24, 2025 • Investing.com
    Stifel Says Compass Pathways Selloff 'Significantly Overdone' After Psilocybin Trial Data
    Jun 24, 2025 • Stocktwits
    Compass plummets as late-stage data on psychedelic asset for depression disappoints.
    Jun 23, 2025 • Seeking Alpha
    Compass Pathways’ COMP360 Psilocybin Shows Benefit in Phase 3 TRD Trial
    Jun 23, 2025 • HCPLive
    Compass Pathways Achieves Phase 3 Trial Success
    Jun 23, 2025 • TipRanks
    Compass Pathways’ Psilocybin Clears First Phase 3 Hurdle
    Jun 23, 2025 • Psychedelic Alpha
    Compass Pathways stock plunges after Phase 3 trial results By Investing.com
    Jun 23, 2025 • Investing.com UK
    Compass psilocybin therapy shown to be effective in largest-ever study in depression
    Jun 23, 2025 • statnews.com
    Compass Pathways Stock Slumps After Positive Late-Stage Trial Results From Psychedelic Drug ‘Underwhelm’ Analysts
    Jun 23, 2025 • Stocktwits
    Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression
    Jun 23, 2025 • Investing News Network
    Evercore Initiates COMPASS Pathways(CMPS.US) With Hold Rating, Announces Target Price $6
    Jun 23, 2025 • 富途牛牛
    Compass Pathways Reports Positive Phase 3 Results For Psilocybin In Treatment-Resistant Depression
    Jun 23, 2025 • Nasdaq
    Compass Pathways succeeds in phase III depression study; stock slides
    Jun 23, 2025 • BioWorld MedTech
    Breakthrough: First-Ever Phase 3 Psilocybin Trial Shows Powerful Depression Treatment Success
    Jun 23, 2025 • Stock Titan
    Despite top-line trial success, Compass going in wrong direction
    Jun 23, 2025 • The Pharma Letter
    Compass Pathways stock slip as psilocybin depression trial falls short of expectations
    Jun 23, 2025 • TradingView
    Compass’ big psychedelic study doesn’t impress investors
    Jun 23, 2025 • BioPharma Dive
    Compass Pathways: Will The Stock Rally Last?
    Jun 23, 2025 • StocksToTrade
    Compass Pathways stock slip as psilocybin trial disappoints
    Jun 23, 2025 • Invezz
    Compass Pathways Stock Is Plunging Today: What's Going On?
    Jun 23, 2025 • Benzinga
    Compass Plots Path to FDA With ‘Meaningful’ Phase III Data for Psilocybin Drug in Depression
    Jun 23, 2025 • BioSpace
    Compass’s Psychedelic Drug to Treat Depression Meets Goal in Trial
    Jun 23, 2025 • Bloomberg.com
    COMP360 Psilocybin for Treatment-Resistant Depression: Positive Phase 3 Efficacy Data
    Jun 23, 2025 • Psychiatric Times
    COMPASS Pathways Approves Key Resolutions at AGM
    Jun 13, 2025 • TipRanks
    Post-Traumatic Stress Disorder Epidemiology and Strategic Analysis Highlight Growth Opportunities in PTSD Market
    Jun 5, 2025 • Research and Markets
    Psychedelic Drugs Markets and Companies Analysis 2025-2029: Shares for Ketamine, GHB, MDMA, Psilocybin, and Other Drugs
    Jun 5, 2025 • Research and Markets
    A new dawn for psychedelics? Compass could be the first to find out
    May 28, 2025 • Endpoints News
    Cowen maintains buy on Compass Pathways, target $23
    May 27, 2025 • Investing.com
    Compass Pathways: Psychedelic Innovator Forging Independent Path With Competition Nearing
    May 14, 2025 • Seeking Alpha
    COMPASS Pathways (CMPS) Upgraded to Buy: Here's What You Should Know
    May 14, 2025 • Nasdaq
    Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
    May 14, 2025 • Business Wire
    Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference
    May 14, 2025 • BioSpace
    Psychedelic: Compass, GH Research, MindMed report quarterly earnings
    May 9, 2025 • Yahoo Finance
    Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
    May 8, 2025 • Investing News Network
    Compass Pathways Announces First Quarter 2025 Financial Results and Business Highlights
    May 8, 2025 • Stock Titan